Trial Profile

A phase-2 study of Doxorubicin microneedle array - SkinJect (D-MNA) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Mar 2025 New trial record
27 Feb 2025 According to Medicus Pharma media release, the high-dose, 200 microgram D-MNA, proposed in the study is the maximum dose that was used in the Company's Phase 1 safety and tolerability study (SKNJCT-001) completed in March 2021.
27 Feb 2025 According to Medicus Pharma media release, Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com